{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024143","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.919634+00:00","generated_at":"2026-06-21T23:14:24.527654+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Finch Q3 net loss $40.4M on $18.1M goodwill impairment; PRISM4 Phase 3 dosing ongoing","bullets":["Net loss $40.4M vs $10.0M in Q3 2021 due to $18.1M goodwill impairment and $11.2M revenue decline from Takeda termination.","Cash and equivalents $85.3M at Sept. 30, 2022; expected runway into Q2 2024, including sublease inflows.","Patient dosing underway in PRISM4 Phase 3 trial of CP101 for recurrent C. diff; topline data anticipated H1 2024.","Howard Franklin appointed Chief Medical Officer; ASD program (FIN-211) suspended; exploring partnerships for IBD candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024143","json":"https://secwatch.observer/filing/0000950170-22-024143.json","markdown":"https://secwatch.observer/filing/0000950170-22-024143.md","text":"https://secwatch.observer/filing/0000950170-22-024143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/0000950170-22-024143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/fnch-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:14:24.527654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e95577732ba57ba8462118e1bad341f3db572b0","claim":"Finch Therapeutics Group, Inc. reported third quarter ended September 30, 2022 results: revenue $11.2 million, net income ($40.4 million).","evidence_excerpt":"net loss was driven by a charge of $18.1 million for the full impairment of the Company’s goodwill during the current quarter. Additionally, there was a decrease in revenue of $11.2 million due to changes under Finch’s collaboration agreement with Takeda, including Takeda’s election in August 2022 to terminate the agreement. Finch also reported an increase in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022024143/0000950170-22-024143-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$11.2 million"},{"label":"Net income","value":"($40.4 million)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}